GSK drops darotropium in favour of GSK573719 for COPD
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has revised its chronic obstructive pulmonary disease (COPD) pipeline, dropping its long-acting muscarinic antagonist (LAMA) darotropium in favour of GSK573719, which has the same mechanism of action. Although darotropium had advanced into Phase IIb trials, GSK573719 is in Phase IIa development. GSK says that the move was made because GSK573719 has a better once-a-day profile in terms of the totality of its performance.